News Search Results
Apr 16, 2026, 08:30 ET Xtalks Named Media Partner for the Toronto Life Sciences and Biotech Summit
the Toronto Life Sciences and Biotech Summit, hosted by Bisnow on May 7, 2026. The event will bring together leaders from commercial real estate, biotechnology, investment and academia to discuss lab leasing trends, innovation district development, talent pipelines and the long-term outlook for life sciences
More news about: Xtalks
Apr 16, 2026, 08:00 ET Brenig Therapeutics to Present Phase 1 Data for BT-267 at the American Academy of Neurology (AAN) 2026 Annual Meeting
BOSTON, April 16, 2026 /PRNewswire/ -- Brenig Therapeutics Inc. (Brenig), a clinical-stage biotechnology company developing brain-penetrant small molecule therapies for neurodegenerative diseases, today announced that data from its ongoing Phase 1 healthy
More news about: Brenig Therapeutics
Apr 16, 2026, 08:00 ET Panome Bio and Audubon Bioscience Partner to Deliver End-to-End FFPE Biospecimen and Metabolomics Solutions for Cancer Researchers
and FFPE. Founded in 2022 and built on the scientific foundation of Washington University in St. Louis, Panome Bio partners with pharmaceutical, biotechnology, and academic research organizations to accelerate discovery across oncology, neuroscience, immunology, and beyond. Learn more at panomebio.com.About
More news about: Panome Bio
Apr 16, 2026, 08:00 ET Bio-Techne Introduces Streamlined Brand Architecture to Help Customers Navigate Solutions Faster and With Greater Clarity
company generated over $1.2 billion in net sales. Its more than 500,000 products are used globally by academic researchers, biopharmaceutical and biotechnology companies, and clinical diagnostic laboratories.For more information on Bio-Techne and its brands, please visit
More news about: Bio-Techne Corporation
Apr 16, 2026, 06:45 ET ACHIEVE-4, the longest Phase 3 study of Lilly's Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Apr 16, 2026, 06:16 ET ATUM Appoints Industry Veteran Gavin Barnard, Ph.D., as Chief Scientific Officer
forward to helping our clients accelerate their most promising therapies into the clinic."About ATUMATUM is a fully integrated biotechnology contract research organization that provides services for gene design, protein engineering, and cell line development. By combining machine learning,
More news about: ATUM
Apr 16, 2026, 05:48 ET Interna Therapeutics Announces Research Collaboration with Daiichi Sankyo to Advance MNM-Based Targeted Delivery Technologies
PETACH TIKVA, Israel, April 16, 2026 /PRNewswire/ -- Interna Therapeutics, a clinical stage biotechnology company advancing its Molecular Nano Motor (MNM) intracellular delivery platform, today announced a research collaboration with Daiichi Sankyo (TSE:
More news about: Interna Therapeutics
Apr 16, 2026, 03:20 ET Harbour BioMed Appoints Dr. Adam Zong as President
portfolio strategy, commercial operations, and business development. His experience spans both multinational pharmaceutical companies and emerging biotechnology organizations. Prior to joining Harbour BioMed, Dr. Zong served as Principal Consultant at Arc Nouvel Clinical Development Consulting. He also served
More news about: Harbour BioMed
Apr 16, 2026, 03:07 ET BIO Asia-Taiwan 2026 to Be Held in Mid-July in Taipei
/PRNewswire/ -- The annual event, BIO Asia–Taiwan 2026, jointly organized by Taiwan Bio Industry Organization (Taiwan BIO) and the global Biotechnology Innovation Organization (BIO), will take place from July 15 to 19 at the Taipei Nangang Exhibition Center, TaiNEX 1 and 2. This year's theme, "Asian
More news about: Taiwan Bio Industry Organization
Apr 15, 2026, 21:21 ET Robbins LLP Encourages ADLX Stockholders Who Lost Money Investing in Aldeyra Therapeutics, Inc. to Contact the Firm for Information About Leading the Class Action
acquired Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) securities between November 3, 2023 and March 16, 2026. Defendant Aldeyra describes itself as "biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated diseases." Pertinent to this action is reproxalap, which
More news about: Robbins LLP
Apr 15, 2026, 21:19 ET Robbins LLP Urges IBRX Stockholders Who Lost Money Investing in ImmunityBio, Inc. to Contact the Firm for Information About Leading the Class Action
investors who purchased or otherwise acquired ImmunityBio, Inc. (NASDAQ: IBRX) securities between January 19, 2026 and March 25, 2026. ImmunityBio is a biotechnology company and ANKTIVA is the Company's lead biologic product.
More news about: Robbins LLP
Apr 15, 2026, 16:05 ET MEDP INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Medpace Holdings Inc. Investors with Substantial Losses Have Opportunity to Lead Action Lawsuit
Medpace is a clinical contract research organization (CRO) focused on providing scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries.The Medpace class action lawsuit alleges that defendants throughout the
More news about: Robbins Geller Rudman & Dowd LLP
Apr 15, 2026, 14:59 ET INVESTOR NOTICE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action - Hagens Berman
844-916-0895ImmunityBio, Inc. (IBRX) Securities Class Action: ImmunityBio is a biotechnology company focused on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system
More news about: Hagens Berman Sobol Shapiro LLP
Apr 15, 2026, 12:03 ET Adimab Collaborator GSK Receives Additional Marketing Approval for Depemokimab
focuses solely on its partners and not on developing an internal product pipeline. Since 2009, Adimab has partnered with over 140 pharmaceutical and biotechnology companies, generating more than 650 therapeutic programs, 90 clinical programs, and 6 approved products. The Adimab technology has been transferred
More news about: Adimab, LLC
Apr 15, 2026, 11:43 ET Downstream Processing Market Trends, Size Surges to USD 20.3 Billion by 2033, Propelled by 6.8% CAGR - Verified Market Reports®
Downstream Processing MarketThe Downstream Processing Market represents a critical value-capture layer within the biopharmaceutical and biotechnology production ecosystem, directly influencing yield efficiency, product purity, and regulatory compliance. This report delivers institutional-grade
More news about: Verified Market Reports
Apr 15, 2026, 10:55 ET Clinical Trial Media Strengthens Platform Leadership to Deliver Faster, More Predictable Enrollment Outcomes with Appointment of Paul Sternhell as Chief Product Officer
2026 /PRNewswire/ -- Clinical Trial Media (CTM), a leading full‑service patient recruitment and retention partner to pharmaceutical and biotechnology companies, today announced that Paul Sternhell has joined the company as Chief Product Officer, strengthening CTM's ability to deliver
More news about: Clinical Trial Media
Apr 15, 2026, 10:01 ET Gene Expression Analysis Market worth $5.93 billion by 2031 | MarketsandMarkets™
The growth in this region is driven by strong genomics research activities, advanced healthcare and research infrastructure, high investments in biotechnology, supportive regulatory frameworks, and the presence of leading market players promoting the adoption of advanced gene expression technologies.Download
More news about: MarketsandMarkets
Apr 15, 2026, 10:00 ET RBL LLC launches Duracyte, advancing living pharmacy platform in Houston's growing biotech hub
Duracyte is a biotechnology company developing implantable "living pharmacy" devices designed to continuously produce therapeutic proteins inside the bodyThe company plans to initiate a Phase 1 clinical trial this year evaluating patients with recurrent ovarian
More news about: RBL LLC
Apr 15, 2026, 10:00 ET Clicklinks | 14-Day Candidate Antibody Discovery - Sanyou AI-STAL 2.0 Defines the Era of Ultimate Speed in Drug Molecule Discovery
foundation for subsequent preclinical development.Looking ahead, Sanyou Bio will continue to delve deeply into the intersection of AI and biotechnology, committed to transforming technological advantages into productive forces that drive industry change. With the continuous evolution of the AI-STAL
More news about: Sanyou Bio
Apr 15, 2026, 09:43 ET Tsingke Unveils 'Zero-Contact' Gene Synthesis to Safeguard Core Genetic Sequences
BEIJING, April 15, 2026 /PRNewswire/ -- As the pace of biotechnology research accelerates, companies are increasingly challenged to balance rapid innovation with the protection of sensitive genetic information. Responding to
More news about: Beijing Tsingke Biotech Co., Ltd.
Apr 15, 2026, 09:43 ET Tsingke Unveils 'Zero-Contact' Gene Synthesis to Safeguard Core Genetic Sequences
BEIJING, April 15, 2026 /PRNewswire/ -- As the pace of biotechnology research accelerates, companies are increasingly challenged to balance rapid innovation with the protection of sensitive genetic information. Responding to
More news about: Beijing Tsingke Biotech Co., Ltd.
Apr 15, 2026, 09:15 ET Intensity Therapeutics Recognized with Pinnacle Award for Excellence in Healthcare Innovation
Intensity Therapeutics, Inc., (Nasdaq: INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary cancer therapies using its non-covalent, drug-conjugation technology that creates
More news about: Intensity Therapeutics Inc.
Apr 15, 2026, 09:10 ET Lunai Bioworks (NASDAQ: LNAI) and Geneial Sign LOI to Build Rare Disease Patient Cohorts for Pharma Partnerships
enabled by these efforts, supporting potential revenue-generating collaborations and downstream partnering opportunities with pharmaceutical and biotechnology partners."Geneial's mission is to accelerate precision medicine by connecting patient communities, researchers, and industry partners," said
More news about: Lunai Bioworks Inc.
Apr 15, 2026, 09:04 ET Wayfinder Biosciences Advances Collaboration with Daiichi Sankyo on Key Neurodegeneration Target to Second Phase
SEATTLE, April 15, 2026 /PRNewswire/ -- Wayfinder Biosciences, a biotechnology company using small molecules to target undruggable proteins at the RNA level, today announced the advancement to the second phase of its research
More news about: Wayfinder Biosciences, Inc.
Apr 15, 2026, 08:39 ET Gallant Reports Positive Pilot Data for Feline Osteoarthritis Stem Cell Therapy; Receives FDA Eligibility for Expanded Conditional Approval Pathway
Gallant, an animal health biotechnology company pioneering off-the-shelf stem cell therapies for pets, today announced positive results from a pilot clinical study evaluating intravenous
More news about: Gallant